|
US6610838B1
|
|
P13 antigens from Borrelia
|
|
EP1012269A2
|
|
P13 antigens from borrelia
|
|
US6143872A
|
|
Borrelia burdorferi Osp A and B proteins and immunogenic peptides
|
|
US6054296A
|
|
66 kDa antigen from Borrelia
|
|
AU7390994A
|
|
Molecular modelling and drug design
|
|
DK75393D0
|
|
Production of protein
|
|
DK72593D0
|
|
RECOMBINANT PROTEIN
|
|
CA2123213A1
|
|
Ganglioside analogs
|
|
WO9308306A1
|
|
Improvement in borrelia burgdorferi diagnosis and prophylaxis
|
|
US5777095A
|
|
Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
|
|
US5248603A
|
|
Superoxide dismutase
|
|
DK8892D0
|
|
Humant proteing
|
|
WO9304171A1
|
|
Human beta-casein, process for producing it and use thereof
|
|
EP0535032A1
|
|
Therapy and prophylaxis of autoimmune diseases
|
|
DK22891A
|
|
Synthetic receptor analogs
|
|
DK240290A
|
|
Fishing vaccine comprehensive and virulent, invasive bacteria
|
|
IL95701D0
|
|
Polypeptide having superoxide dismutating property
|
|
DK141690D0
|
|
Use of monoclonal antibodies
|
|
DK455789D0
|
|
polypeptide
|
|
WO8909616A1
|
|
Fish vaccine comprising a virulent, invasive bacterium
|
